A) Cumulative count and b) percent cumulative use of the different pulmonary function test (PFT) measures as longitudinal outcomes for systemic sclerosis-associated.

Slides:

Advertisements

Similar presentations

Core Pulmonary Concepts. Lung volumes and capacities.

Advertisements

SPIROMETRY (Pulmonary Function Testing)

Pulmonary response in sarcoidosis

Brandon Stone, MD, Victor S. Mangona, MD, Matthew D

Longitudinal change in FVC, DLCO and RBC:TP.

Summary findings regarding the efficacy/safety profile across xanthines in chronic obstructive pulmonary disease patients. a) Combined plot of the change.

Brandon Stone, MD, Victor S. Mangona, MD, Matthew D

Chronic Obstructive Pulmonary Disease: An Evidence-Based Approach to Treatment With a Focus on Anticholinergic Bronchodilation Nicholas J. Gross, MD,

Flow diagram summarising the most important effects of biochemical (left) and mechanical (right) pregnancy-induced factors on pulmonary function, ventilatory.

High-resolution computed tomography (HRCT) features of interstitial lung abnormalities. a) HRCT of a 56-year-old patient whose mother died of idiopathic.

Immunostaining for lipid peroxidation product 4-hydroxy-2-nonenal (4-HNE) adduct in the lungs of smokers with and without chronic obstructive pulmonary.

Radiology assessment of pulmonary amyloidosis

A) Forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio as a function of age showing individuals with FEV1/FVC ratio less than the.

Effects of Extended Pleurectomy and Decortication on Quality of Life and Pulmonary Function in Patients With Malignant Pleural Mesothelioma David Burkholder,

Schematic representation of breathing levels during positive expiratory pressure in an obstructed patient. Schematic representation of breathing levels.

Changes of a) spirometric, plethysmographic, and b) impedance data at 5 Hz induced by bronchodilator in flow limited (□) and nonflow limited (▓) patients.

Supreme laryngeal mask airway for laparoscopic cholecystectomy in patient with severe pulmonary fibrosis M. Carron, A. Marchet, C. Ori British Journal.

Sporadic Obliterative Bronchiolitis: Case Series and Systematic Review of the Literature Sean J. Callahan, MD, Andrew Vranic, MD, Lucia Flors, MD, Michael.

REVEAL pulmonary arterial hypertension (PAH) risk score.

a) Chest radiograph showing bilateral coarse interstitial shadowing

Impact of immunosuppressive therapy on pulmonary function, recurrence of diffuse alveolar haemorrhage (DAH) and chest computed tomography (CT) findings.

An algorithm for the early diagnosis of pulmonary arterial hypertension in systemic sclerosis. An algorithm for the early diagnosis of pulmonary arterial.

Expanded version of the early part of a subject's volume–time spirogram, illustrating back-extrapolation through the steepest part of the curve, where.

Extent of interstitial lung disease (ILD) in patients with systemic sclerosis-associated ILD. A simple stratification that utilises pulmonary function.

Representative diaphragm electromyogram (EMG) tracings at rest (a and b) and during maximum voluntary ventilation (c and d) in a healthy subject (a and.

Changes in operating lung volumes are shown as ventilation increases with exercise in a) age-matched normal subjects (n = 25) and b) chronic obstructive.

Schematic representation of the current evidence for the association of cadmium exposure with smoking-related lung disease including chronic obstructive.

تست عملکرد ریوی SPIROMETERY.

Patient case study 2—fibrotic uILD in the setting of IPAF

Forest plots of the correlation between high-resolution computed tomography (HRCT) scores and pulmonary function test values. Forest plots of the correlation.

3-year survival of lung cancer patients in the general population and in those with a prior diagnosis of chronic obstructive pulmonary disease (COPD).

Simplified REVEAL (Registry to Evaluate Early And Long-term PAH Disease Management) risk score. Simplified REVEAL (Registry to Evaluate Early And Long-term.

Proposed screening algorithm for identification of pulmonary arterial hypertension (PAH) associated with connective tissue disease. Proposed screening.

Michael T. Durheim, MD, Sunghee Kim, PhD, Brian C

A summary of the pathogenesis, pathophysiology and clinical implications of the pulmonary vascular and cardiac abnormalities in interstitial lung disease.

Cumulative count of the different primary pulmonary function test (PFT) outcomes in longitudinal studies of systemic sclerosis-associated interstitial.

Time to disease progression or death in a) the whole Bosentan Use in Interstitial Lung Disease (BUILD)-1 study population and b) the subpopulation with.

Post-bronchodilator forced expiratory volume in 1 s (FEV1) to forced vital capacity (FVC) ratio in subjects aged >50 yrs. Post-bronchodilator forced expiratory.

Simplified diagram of the multidisciplinary process to diagnose interstitial lung disease, including a clinician, radiologist, pathologist and also a geneticist:

Algorithm for the assessment of fitness to fly in chronic obstructive pulmonary disease patients. Algorithm for the assessment of fitness to fly in chronic.

Change in forced vital capacity (FVC) % predicted (% pred) per week from baseline in the CAPACITY 004 and 006 study comparing pirfenidone (2403 mg·day−1)

Predicted Versus Observed FEV1 and Dlco After Major Lung Resection: A Prospective Evaluation at Different Postoperative Periods Alessandro Brunelli,

Proportion of patients in each World Health Organization functional class (WHO-FC) at the time of pulmonary arterial hypertension-associated systemic sclerosis.

Physician perspectives on the most useful methods for monitoring α1-antitrypsin deficiency in the clinical trial setting versus clinical practice. Physician.

Forest plot of the a) sensitivity and b) specificity of different pulmonary function test screening algorithms for the presence of systemic sclerosis-associated.

Effects of N-acetylcysteine (▒) and placebo (░) on vital capacity (VC) and diffusing capacity of the lung for carbon monoxide (DL,CO) depending on baseline.

Change in physiological variables from baseline values a) at rest and b) during exercise after saline infusion and exposition to different β-blocker agents.

Pathophysiology of obesity hypoventilation syndrome (OHS).

In a representative chronic heart failure patient, tidal flow-volume loops at rest (solid line) and at the peak of symptom-limited incremental exercise.

Representative pressure tracings of a) pulmonary arterial pressure and b) pulmonary arterial wedge pressure (PAWP). Representative pressure tracings of.

Relationship between a) forced expiratory flow at 25–75% of forced vital capacity (FVC) (FEF25–75%) and b) forced expiratory flow at 75% of FVC (FEF75%)

Proportion of participants with access to a, b) a radiologist and c, d) a pathologist experienced in interstitial lung diseases to discuss cases of suspected.

Cumulative mortality over 60 months in patients with α1-antitrypsin deficiency and an initial forced expiratory volume in 1 s

A) Tidal volume (VT) (presented as % predicted of vital capacity (VC)), b) breathing frequency (Fb), c) dynamic inspiratory capacity (IC) and d) inspiratory.

Lung function adjusted for body length and gestational age in male and female premature infants. Lung function adjusted for body length and gestational.

Correlation between inspiratory capacity (IC)/total lung capacity (TLC) ratio and oxygen pulse at peak exercise in chronic obstructive pulmonary disease.

Distribution of diffusing capacity of the lung for carbon monoxide (DLCO) among 243 scleroderma patients who underwent right heart catheterisation (RHC)

Progression in the patient’s pulmonary function tests from 2010 to a) Forced vital capacity (FVC); b) total lung capacity (TLC); c) diffusing capacity.

Chronic obstructive pulmonary disease (COPD) prevalence (postbronchodilator FEV1/FVC (forced expiratory volume in 1 s/forced vital capacity)

A) Operating lung volumes and b) breathing frequency (Fb) during incremental cycle exercise in patients with moderate chronic obstructive pulmonary disease.

Is pulmonary function damaged by neoadjuvant lung cancer therapy

Endobronchial valve (EBV) treatment for emphysema, summary of treatment selection and outcome. Endobronchial valve (EBV) treatment for emphysema, summary.

Mean change from baseline in percentage predicted forced vital capacity (FVC) in the a) phase III CAPACITY [27] and b) ASCEND [14] studies. #: n=174; ¶:

Baseline New York Heart Association functional class (NYHA FC) predicts survival in patients with pulmonary hypertension using infused epoprostenol therapy.

Flow–volume loops of test breaths and preceding control breaths of three representative chronic obstructive pulmonary disease patients with different degrees.

High-resolution computed tomography images of smoking-related interstitial lung diseases (ILDs). a) Pulmonary Langerhans cell histiocytosis, b) respiratory.

Schematic diagram of the DETECT study [56].

A) Smokers’ macrophages show a fine, golden haemosiderin cytoplasmic pigment; b) in respiratory bronchiolitis (RB), smokers’ macrophages are located in.

Tracing of tidal breathing followed by an inspiratory manoeuvre to total lung capacity (TLC) to record inspiratory capacity (IC), followed by a full expiration.

Comparison of total lung capacity (TLC), slow vital capacity (SVC) and carbon monoxide transfer factor (Tlco) in patients with stable interstitial lung.

Presentation transcript:

a) Cumulative count and b) percent cumulative use of the different pulmonary function test (PFT) measures as longitudinal outcomes for systemic sclerosis-associated interstitial lung disease progression. a) Cumulative count and b) percent cumulative use of the different pulmonary function test (PFT) measures as longitudinal outcomes for systemic sclerosis-associated interstitial lung disease progression. For each year, percent cumulative use was calculated by dividing the cumulative use of each PFT measure by the cumulative number of published articles. No distinctions were made between absolute and % predicted PFT values. All variations of diffusing capacity of the lung for carbon monoxide (DLCO) were grouped together into one all-encompassing DLCO measure. Other PFTs included measures of forced expiratory flow over the mid-half of forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1)/FVC, FEV1/vital capacity (VC), functional residual capacity, residual volume and total lung capacity (TLC). Melissa Caron et al. Eur Respir Rev 2018;27:170102 ©2018 by European Respiratory Society